Nasdaq · CIK 0001802665
HRMY Harmony Biosciences Holdings, Inc.
Insider trading from SEC Form 4. Last filing 24 d ago. Close $40.28 on Oct 9, 2026, +56% from the 52-week low and -6% from the high.
Last 90 days
Net insider value
-$3.1M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$3.1M by 1 insider
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
HRMYOct 9, 2026 · close 40.28
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Harmony Biosciences Holdings, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Kumar Budur CHIEF MEDICAL OFFICER sell | $1.7M 38,452 shares | -258% | - | |
| 25Weak | Kumar Budur CHIEF MEDICAL OFFICER sell | $1.5M 33,954 shares | -141% | - | |
| 18Weak | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $139k 3,746 shares | -13% | +44% from low-8% from high | |
| 44Moderate | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $753k 20,961 shares | -100% | +41% from low-10% from high | |
| 43Moderate | Jeffrey M. Dayno PRESIDENT, CEO sell | $1.0M 25,933 shares | -130% | +56% from low0% from high | |
| 37Weak | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $791k 20,000 shares | -100% | +54% from low-2% from high | |
| 32Weak | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $120k 3,427 shares | -100% | +32% from low-15% from high | |
| 44Moderate | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $787k 21,573 shares | -100% | +32% from low-11% from high | |
| 35Weak | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $227k 6,987 shares | -100% | +2% from low-22% from high | |
| 11Weak | Jeffrey Dierks CHIEF COMMERCIAL OFFICER sell | $159k 4,869 shares | -100% | - | |
| 34Weak | Jeffrey Dierks CHIEF COMMERCIAL OFFICER sell | $552k 14,754 shares | -112% | - | |
| 30Weak | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $68k 1,775 shares | -100% | - | |
| 47Moderate | Jeffrey M. Dayno PRESIDENT, CEO sell | $774k 19,293 shares | -100% | - | |
| 47Moderate | Sandip Kapadia CHIEF FINANCIAL OFFICER sell | $1.0M 25,000 shares | -100% | - | |
| 40Moderate | Jeffrey Dierks CHIEF COMMERCIAL OFFICER sell | $1.1M 30,598 shares | -104% | - | |
| 31Weak | Jeffrey Dierks CHIEF COMMERCIAL OFFICER sell | $389k 10,507 shares | -100% | - | |
| 28Weak | Jeffrey Dierks CHIEF COMMERCIAL OFFICER sell | $266k 7,180 shares | -100% | - | |
| 65Notable | Antonio J. Gracias director, owner sell | $139M 4,600,000 shares | -41% | - | |
| 62Notable | Marshman Fund Trust II owner sell | $139M 4,600,000 shares | -43% | - | |
| 38Weak | Jeffrey Dierks CHIEF COMMERCIAL OFFICER sell | $870k 21,496 shares | -100% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +900 | $30.69 | $28k | 14,015 | 24 d ago |
| Sep 16, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +900 | $30.27 | $27k | 14,915 | 24 d ago |
| Sep 16, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,800 | $43.01 | $77k | 13,115 | 24 d ago |
| Sep 17, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +400 | $30.69 | $12k | 13,515 | 24 d ago |
| Sep 17, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +400 | $30.27 | $12k | 13,915 | 24 d ago |
| Sep 17, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -800 | $43.00 | $34k | 13,115 | 24 d ago |
| Sep 18, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +10,406 | $30.69 | $319k | 23,521 | 24 d ago |
| Sep 18, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +25,446 | $30.27 | $770k | 48,967 | 24 d ago |
| Sep 18, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -35,852 | $43.05 | $1.5M | 13,115 | 24 d ago |
| Sep 16, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -900 | $0.00 | $0 | 29,400 | 24 d ago |
| Sep 16, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -900 | $0.00 | $0 | 63,346 | 24 d ago |
| Sep 17, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -400 | $0.00 | $0 | 29,000 | 24 d ago |
| Sep 17, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -400 | $0.00 | $0 | 62,946 | 24 d ago |
| Sep 18, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -10,406 | $0.00 | $0 | 18,594 | 24 d ago |
| Sep 18, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -25,446 | $0.00 | $0 | 37,500 | 24 d ago |
| Sep 4, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -5,500 | $41.98 | $231k | 18,615 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -4,500 | $42.25 | $190k | 14,115 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $42.79 | $43k | 13,115 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +12,200 | $30.69 | $374k | 25,315 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +10,754 | $30.27 | $326k | 36,069 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -22,954 | $43.10 | $989k | 13,115 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -12,200 | $0.00 | $0 | 30,300 | 33 d ago |
| Sep 8, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Stock Optionderivative | -10,754 | $0.00 | $0 | 64,246 | 33 d ago |
| Jan 26, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,746 | $37.15 | $139k | 24,521 | Jan 28, 2026 |
| Jan 24, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +2,188 | $0.00 | $0 | 2,188 | Jan 26, 2026 |
| Jan 22, 2026 | Adam H. Zaeske CHIEF COMMERCIAL OFFICER | AGrant or award Stock Optionderivative | +56,900 | $0.00 | $0 | 56,900 | Jan 26, 2026 |
| Jan 24, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Common Stock | +10,500 | $0.00 | $0 | 10,500 | Jan 26, 2026 |
| Jan 24, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +3,813 | $0.00 | $0 | 3,813 | Jan 26, 2026 |
| Jan 24, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | MOption exercise Common Stock | +2,500 | $0.00 | $0 | 2,500 | Jan 26, 2026 |
| Jan 24, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,153 | $36.82 | $42k | 1,035 | Jan 26, 2026 |
| Jan 24, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | FTax withholding Common Stock | -4,785 | $36.82 | $176k | 5,715 | Jan 26, 2026 |
| Jan 24, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -2,239 | $36.82 | $82k | 1,574 | Jan 26, 2026 |
| Jan 24, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | FTax withholding Common Stock | -1,116 | $36.82 | $41k | 1,384 | Jan 26, 2026 |
| Jan 22, 2026 | Adam H. Zaeske CHIEF COMMERCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +16,200 | $0.00 | $0 | 16,200 | Jan 26, 2026 |
| Jan 25, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | MOption exercise Common Stock | +2,600 | $0.00 | $0 | 2,600 | Jan 26, 2026 |
| Jan 25, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +2,662 | $0.00 | $0 | 2,662 | Jan 26, 2026 |
| Jan 25, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Common Stock | +13,000 | $0.00 | $0 | 13,000 | Jan 26, 2026 |
| Jan 25, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +4,725 | $0.00 | $0 | 4,725 | Jan 26, 2026 |
| Jan 25, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,372 | $36.82 | $51k | 1,290 | Jan 26, 2026 |
| Jan 25, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -2,553 | $36.82 | $94k | 2,172 | Jan 26, 2026 |
| Jan 25, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | FTax withholding Common Stock | -1,126 | $36.82 | $41k | 1,474 | Jan 26, 2026 |
| Jan 25, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | FTax withholding Common Stock | -5,654 | $36.82 | $208k | 7,346 | Jan 26, 2026 |
| Jan 22, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | AGrant or award Stock Optionderivative | +42,600 | $0.00 | $0 | 42,600 | Jan 26, 2026 |
| Jan 22, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | AGrant or award Stock Optionderivative | +184,600 | $0.00 | $0 | 184,600 | Jan 26, 2026 |
| Jan 22, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | AGrant or award Stock Optionderivative | +42,600 | $0.00 | $0 | 42,600 | Jan 26, 2026 |
| Jan 22, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | AGrant or award Stock Optionderivative | +42,600 | $0.00 | $0 | 42,600 | Jan 26, 2026 |
| Jan 22, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +12,200 | $0.00 | $0 | 12,200 | Jan 26, 2026 |
| Jan 22, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | AGrant or award Restricted Stock Unitsderivative | +52,900 | $0.00 | $0 | 52,900 | Jan 26, 2026 |
| Jan 22, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +12,200 | $0.00 | $0 | 12,200 | Jan 26, 2026 |
| Jan 22, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | AGrant or award Restricted Stock Unitsderivative | +12,200 | $0.00 | $0 | 12,200 | Jan 26, 2026 |
| Jan 24, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -2,188 | $0.00 | $0 | 4,175 | Jan 26, 2026 |
| Jan 24, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Restricted Stock Unitsderivative | -10,500 | $0.00 | $0 | 21,000 | Jan 26, 2026 |
| Jan 24, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -3,813 | $0.00 | $0 | 7,625 | Jan 26, 2026 |
| Jan 24, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | MOption exercise Restricted Stock Unitsderivative | -2,500 | $0.00 | $0 | 5,000 | Jan 26, 2026 |
| Jan 25, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -4,725 | $0.00 | $0 | 14,175 | Jan 26, 2026 |
| Jan 25, 2026 | Andrew Serafin CHIEF STRATEGY OFFICER | MOption exercise Restricted Stock Unitsderivative | -2,600 | $0.00 | $0 | 7,800 | Jan 26, 2026 |
| Jan 25, 2026 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -2,662 | $0.00 | $0 | 7,988 | Jan 26, 2026 |
| Jan 25, 2026 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Restricted Stock Unitsderivative | -13,000 | $0.00 | $0 | 39,000 | Jan 26, 2026 |
| Jan 15, 2026 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -20,961 | $35.92 | $753k | 0 | Jan 20, 2026 |
| Dec 12, 2025 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Common Stock10b5-1 | +20,000 | $8.22 | $164k | 20,000 | Dec 17, 2025 |
| Dec 12, 2025 | Jeffrey M. Dayno PRESIDENT, CEO | SOpen-market sale Common Stock10b5-1 | -20,000 | $40.11 | $802k | 0 | Dec 17, 2025 |
| Dec 12, 2025 | Jeffrey M. Dayno PRESIDENT, CEO | SOpen-market sale Common Stock10b5-1 | -5,933 | $40.11 | $238k | 0 | Dec 17, 2025 |
| Dec 12, 2025 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Stock Optionderivative10b5-1 | -20,000 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 5, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +20,000 | $29.03 | $581k | 20,000 | Dec 9, 2025 |
| Dec 5, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -20,000 | $39.54 | $791k | 0 | Dec 9, 2025 |
| Dec 5, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Stock Optionderivative10b5-1 | -20,000 | $0.00 | $0 | 185,000 | Dec 9, 2025 |
| Nov 21, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,427 | $35.00 | $120k | 0 | Nov 25, 2025 |
| Sep 30, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +45,000 | $0.00 | $0 | 45,000 | Oct 2, 2025 |
| Sep 30, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -24,039 | $27.56 | $663k | 20,961 | Oct 2, 2025 |
| Sep 30, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -45,000 | $0.00 | $0 | 45,000 | Oct 2, 2025 |
| Aug 28, 2025 | Antonio J. Gracias director, owner | JOther Common Stock | -6,618,033 | - | - | 0 | Sep 2, 2025 |
| Aug 15, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -21,573 | $36.50 | $787k | 0 | Aug 19, 2025 |
| May 25, 2025 | R. Mark Graf director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 15, 2025 | Peter Anastasiou director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 15, 2025 | Antonio J. Gracias director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 15, 2025 | Gary Sender director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 15, 2025 | Linda M Szyper director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 15, 2025 | Ron M Philip director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 15, 2025 | Juan A. Sabater director | AGrant or award Stock Optionderivative | +14,522 | $0.00 | $0 | 14,522 | May 16, 2025 |
| May 1, 2025 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +18,750 | $0.00 | $0 | 18,750 | May 9, 2025 |
| May 1, 2025 | Kumar Budur CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -8,869 | $29.86 | $265k | 9,881 | May 9, 2025 |
| May 1, 2025 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -18,750 | $0.00 | $0 | 18,750 | May 9, 2025 |
| Apr 7, 2025 | Adam H. Zaeske CHIEF COMMERCIAL OFFICER | AGrant or award Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Apr 16, 2025 |
| Apr 7, 2025 | Adam H. Zaeske CHIEF COMMERCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +30,000 | $0.00 | $0 | 30,000 | Apr 16, 2025 |
| Apr 2, 2025 | Ron M Philip director | AGrant or award Stock Optionderivative | +14,077 | $0.00 | $0 | 14,077 | Apr 4, 2025 |
| Apr 1, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -6,247 | $32.48 | $203k | 740 | Apr 3, 2025 |
| Apr 1, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -740 | $33.12 | $25k | 0 | Apr 3, 2025 |
| Mar 29, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +15,000 | $0.00 | $0 | 15,000 | Apr 1, 2025 |
| Mar 29, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -8,014 | $33.19 | $266k | 6,986 | Apr 1, 2025 |
| Mar 29, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Restricted Stock Unitsderivative | -15,000 | $0.00 | $0 | 15,000 | Apr 1, 2025 |
| Mar 3, 2025 | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +4,869 | $8.22 | $40k | 4,869 | Mar 5, 2025 |
| Mar 3, 2025 | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -4,369 | $32.61 | $142k | 500 | Mar 5, 2025 |
| Mar 3, 2025 | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -500 | $33.23 | $17k | 0 | Mar 5, 2025 |
| Mar 3, 2025 | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | MOption exercise Stock Optionderivative10b5-1 | -4,869 | $0.00 | $0 | 0 | Mar 5, 2025 |
| Jan 24, 2025 | Sandip Kapadia CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +3,812 | $0.00 | $0 | 3,812 | Jan 28, 2025 |
| Jan 24, 2025 | Andrew Serafin CHIEF STRATEGY OFFICER | MOption exercise Common Stock | +2,500 | $0.00 | $0 | 2,500 | Jan 28, 2025 |
| Jan 24, 2025 | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +13,125 | $30.69 | $403k | 13,125 | Jan 28, 2025 |
| Jan 24, 2025 | Jeffrey M. Dayno PRESIDENT, CEO | MOption exercise Common Stock | +10,500 | $0.00 | $0 | 10,500 | Jan 28, 2025 |
| Jan 24, 2025 | Kumar Budur CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +2,187 | $0.00 | $0 | 2,187 | Jan 28, 2025 |
| Jan 24, 2025 | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -8,000 | $36.94 | $296k | 5,125 | Jan 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Peter Anastasioudirector
- Kumar BudurCHIEF MEDICAL OFFICER
- Jeffrey M. DaynoPRESIDENT, CEO
- Jeffrey DierksCHIEF COMMERCIAL OFFICER
- Antonio J. Graciasdirector, owner
- R. Mark Grafdirector
- Sandip KapadiaCHIEF FINANCIAL OFFICER
- Marshman Fund Trust IIowner
- Ron M Philipdirector
- Juan A. Sabaterdirector, owner
- Gary Senderdirector
- Andrew SerafinCHIEF STRATEGY OFFICER
- Linda M Szyperdirector
- Adam H. ZaeskeCHIEF COMMERCIAL OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.